Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables: 2012-2018

Historic Change in Account Payables for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Dec 2018 value amounting to $3.4 million.

  • Ultragenyx Pharmaceutical's Change in Account Payables rose 298.58% to $3.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.2 million, marking a year-over-year increase of 517.67%. This contributed to the annual value of $3.4 million for FY2018, which is 2.52% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Change in Account Payables of $3.4 million as of FY2018, which was down 2.52% from $3.5 million recorded in FY2017.
  • Ultragenyx Pharmaceutical's 5-year Change in Account Payables high stood at $3.5 million for FY2017, and its period low was -$2.0 million during FY2015.
  • In the last 3 years, Ultragenyx Pharmaceutical's Change in Account Payables had a median value of $3.4 million in 2018 and averaged $3.1 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Change in Account Payables soared by 1,240.51% in 2014, and later crashed by 162.39% in 2015.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Account Payables (Yearly) stood at $3.2 million in 2014, then crashed by 162.39% to -$2.0 million in 2015, then soared by 226.24% to $2.5 million in 2016, then soared by 38.25% to $3.5 million in 2017, then fell by 2.52% to $3.4 million in 2018.